A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)

  • Arulananda, Surein (Primary Chief Investigator (PCI))

Project: Research

Project Details

Short titleeVOLVE-Meso
StatusActive
Effective start/end date5/03/24 → 4/03/29